Mendus AB (publ) (IMMU) - Net Assets
Based on the latest financial reports, Mendus AB (publ) (IMMU) has net assets worth Skr585.07 Million SEK (≈ $62.96 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr628.32 Million ≈ $67.62 Million USD) and total liabilities (Skr43.26 Million ≈ $4.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IMMU cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr585.07 Million |
| % of Total Assets | 93.12% |
| Annual Growth Rate | 32.36% |
| 5-Year Change | -10.91% |
| 10-Year Change | 471.43% |
| Growth Volatility | 99.35 |
Mendus AB (publ) - Net Assets Trend (2009–2025)
This chart illustrates how Mendus AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore IMMU asset base for the complete picture of this company's asset base.
Annual Net Assets for Mendus AB (publ) (2009–2025)
The table below shows the annual net assets of Mendus AB (publ) from 2009 to 2025. For live valuation and market cap data, see market value of Mendus AB (publ).
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr585.07 Million ≈ $62.96 Million |
-9.31% |
| 2024-12-31 | Skr645.15 Million ≈ $69.43 Million |
-8.45% |
| 2023-12-31 | Skr704.73 Million ≈ $75.84 Million |
+36.99% |
| 2022-12-31 | Skr514.44 Million ≈ $55.36 Million |
-21.67% |
| 2021-12-31 | Skr656.74 Million ≈ $70.68 Million |
-0.66% |
| 2020-12-31 | Skr661.09 Million ≈ $71.14 Million |
+142.35% |
| 2019-12-31 | Skr272.78 Million ≈ $29.36 Million |
-32.82% |
| 2018-12-31 | Skr406.04 Million ≈ $43.70 Million |
+114.21% |
| 2017-12-31 | Skr189.56 Million ≈ $20.40 Million |
+85.14% |
| 2016-12-31 | Skr102.39 Million ≈ $11.02 Million |
-26.44% |
| 2015-12-31 | Skr139.18 Million ≈ $14.98 Million |
+115.36% |
| 2014-12-31 | Skr64.63 Million ≈ $6.95 Million |
-35.53% |
| 2013-12-31 | Skr100.24 Million ≈ $10.79 Million |
+307.42% |
| 2012-12-31 | Skr24.60 Million ≈ $2.65 Million |
+222.62% |
| 2011-12-31 | Skr7.63 Million ≈ $820.73K |
+94.56% |
| 2010-12-31 | Skr3.92 Million ≈ $421.83K |
-40.52% |
| 2009-12-31 | Skr6.59 Million ≈ $709.20K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mendus AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 96953793400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr62.59 Million | 10.70% |
| Other Components | Skr1.50 Billion | 255.63% |
| Total Equity | Skr585.07 Million | 100.00% |
Mendus AB (publ) Competitors by Market Cap
The table below lists competitors of Mendus AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gabriel Resources Ltd
V:GBU
|
$33.84 Million |
|
Acarix A/S
ST:ACARIX
|
$33.84 Million |
|
Inbest Prime IV Inmuebles SOCIMI S.A.
MC:YINB4
|
$33.85 Million |
|
POLARIS WORKS Inc
KQ:123010
|
$33.86 Million |
|
Sterling Metals Corp
V:SAG
|
$33.83 Million |
|
Subur Tiasa Holdings Bhd
KLSE:6904
|
$33.83 Million |
|
Puloon Technology Inc
KQ:094940
|
$33.81 Million |
|
Atende S.A.
WAR:ATD
|
$33.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mendus AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 645,149,000 to 585,066,000, a change of -60,083,000 (-9.3%).
- Net loss of 113,258,000 reduced equity.
- Share repurchases of 52,500,000 reduced equity.
- Other comprehensive income increased equity by 3,448,000.
- Other factors increased equity by 102,227,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-113.26 Million | -19.36% |
| Share Repurchases | Skr52.50 Million | -8.97% |
| Other Comprehensive Income | Skr3.45 Million | +0.59% |
| Other Changes | Skr102.23 Million | +17.47% |
| Total Change | Skr- | -9.31% |
Book Value vs Market Value Analysis
This analysis compares Mendus AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 13.80x to 0.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | Skr0.37 | Skr5.13 | x |
| 2010-12-31 | Skr0.22 | Skr5.13 | x |
| 2011-12-31 | Skr0.43 | Skr5.13 | x |
| 2012-12-31 | Skr1.48 | Skr5.13 | x |
| 2013-12-31 | Skr5.68 | Skr5.13 | x |
| 2014-12-31 | Skr2.77 | Skr5.13 | x |
| 2015-12-31 | Skr5.92 | Skr5.13 | x |
| 2016-12-31 | Skr3.64 | Skr5.13 | x |
| 2017-12-31 | Skr6.73 | Skr5.13 | x |
| 2018-12-31 | Skr7.28 | Skr5.13 | x |
| 2019-12-31 | Skr3.40 | Skr5.13 | x |
| 2020-12-31 | Skr7.99 | Skr5.13 | x |
| 2021-12-31 | Skr3.29 | Skr5.13 | x |
| 2022-12-31 | Skr2.38 | Skr5.13 | x |
| 2023-12-31 | Skr30.47 | Skr5.13 | x |
| 2024-12-31 | Skr13.26 | Skr5.13 | x |
| 2025-12-31 | Skr9.55 | Skr5.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mendus AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-19.36%) is above the historical average (-33.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -34.71% | 0.00% | 0.00x | 1.17x | Skr-2.95 Million |
| 2010 | -68.12% | 0.00% | 0.00x | 1.59x | Skr-3.06 Million |
| 2011 | -34.48% | -52586.50% | 0.00x | 1.22x | Skr-3.39 Million |
| 2012 | -28.00% | 0.00% | 0.00x | 1.09x | Skr-9.35 Million |
| 2013 | -16.14% | 0.00% | 0.00x | 1.09x | Skr-26.20 Million |
| 2014 | -55.11% | 0.00% | 0.00x | 1.10x | Skr-42.08 Million |
| 2015 | -31.56% | 0.00% | 0.00x | 1.11x | Skr-57.84 Million |
| 2016 | -71.87% | 0.00% | 0.00x | 1.19x | Skr-83.83 Million |
| 2017 | -42.38% | 0.00% | 0.00x | 1.30x | Skr-99.29 Million |
| 2018 | -24.10% | 0.00% | 0.00x | 1.11x | Skr-138.46 Million |
| 2019 | -49.75% | -814.09% | 0.05x | 1.11x | Skr-162.99 Million |
| 2020 | -13.99% | 0.00% | 0.00x | 1.10x | Skr-158.58 Million |
| 2021 | -20.81% | -2278233.33% | 0.00x | 1.10x | Skr-202.37 Million |
| 2022 | -26.63% | -4573.99% | 0.00x | 1.21x | Skr-188.43 Million |
| 2023 | -14.42% | -356.72% | 0.04x | 1.07x | Skr-172.09 Million |
| 2024 | -19.90% | -2543.56% | 0.01x | 1.08x | Skr-192.91 Million |
| 2025 | -19.36% | 0.00% | 0.00x | 1.07x | Skr-171.76 Million |
Industry Comparison
This section compares Mendus AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mendus AB (publ) (IMMU) | Skr585.07 Million | -34.71% | 0.07x | $33.83 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more